Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 9/20 | 0.75 |
| ▸ | CA1 | P00915 | 9/20 | 0.75 |
| ▸ | CA2 | P00918 | 9/20 | 0.75 |
| ▸ | CA7 | P43166 | 9/20 | 0.75 |
| ▸ | CA9 | Q16790 | 9/20 | 0.75 |
| ▸ | CA14 | Q9ULX7 | 9/20 | 0.75 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31498357 | 0.86 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL40169 | 0.86 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL24991266 | 0.81 | CA12 (0.73) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7092474 | 0.81 | CA12 (0.73) | CA12CA1CA2CA7CA9 | |
| SCHEMBL39467 | 0.80 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6518821 | 0.80 | CA12 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5195832 | 0.79 | LMNA (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23484284 | 0.78 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| Methyl 2,5-Dihydroxybenzoate SCHEMBL38890 | 0.76 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Methyl 2,5-Dihydroxybenzoate SCHEMBL29457577 | 0.76 | CA12 (1.00) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9968608-B2 | Pharmaceutical compositions comprising pemetrexed and tromethamine | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2018-05-15 | — | — | US | claimed |
| US-20160310495-A1 | PHARMACEUTICAL COMPOSITIONS OF PEMETREXED | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2016-10-27 | — | — | US | claimed |
| US-9421207-B2 | Pharmaceutical compositions comprising pemetrexed and tromethamine | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2016-08-23 | — | — | US | claimed |
| US-20150111905-A1 | PHARMACEUTICAL COMPOSITIONS OF PEMETREXED | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2015-04-23 | — | — | US | claimed |
| EP-2854768-A1 | PHARMACEUTICAL COMPOSITIONS OF PEMETREXED | Fresenius Kabi Oncology Limited (IN) | 2015-04-08 | — | — | EP | claimed |
| WO-2013179248-A1 | PHARMACEUTICAL COMPOSITIONS OF PEMETREXED | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2013-12-05 | — | — | WO | claimed |
| EP-2854768-B2 | PHARMACEUTICAL COMPOSITIONS OF PEMETREXED | FRESENIUS KABI ONCOLOGY LTD (IN) | 2025-06-18 | — | — | EP | disclosed |
| US-12115164-B2 | Pemetrexed formulations | EAGLE PHARMACEUTICALS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240009199-A1 | PEMETREXED FORMULATIONS | EAGLE PHARMACEUTICALS, INC. | 2024-01-11 | — | — | US | disclosed |
| US-20240009198-A1 | PEMETREXED FORMULATIONS | EAGLE PHARMACEUTICALS, INC. | 2024-01-11 | — | — | US | disclosed |
| US-20230414623-A1 | PEMETREXED FORMULATIONS | EAGLE PHARMACEUTICALS, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230390295-A1 | PEMETREXED FORMULATIONS | EAGLE PHARMACEUTICALS, INC. | 2023-12-07 | — | — | US | disclosed |
| EP-3743072-B1 | PHARMACEUTICAL COMPOSITION FOR SUSTAINED RELEASE DELIVERY OF BUPRENORPHINE | FORESEE PHARMACEUTICALS CO LTD (TW) | 2023-10-25 | — | — | EP | disclosed |
| WO-2010030598-A2 | PHARMACEUTICAL FORMULATIONS COMPRISING PEMETREXED | DR. REDDY'S LABORATORIES LIMITED (IN) | 2010-03-18 | — | — | WO | disclosed |
| CN-101081301-A | Medicinal composition containing pemetrexed | HAINAN TIANYUANKANGZE PHARMACE (CN) | 2007-12-05 | — | — | CN | disclosed |
| EP-1265612-B1 | PHARMACEUTICAL COMPOSITION COMPRISING PEMETREXED TOGETHER WITH MONOTHIOGLYCEROL, L-CYSTEIN OR THIOGLYCOLIC ACID | LILLY CO ELI (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6686365-B2 | Pharmaceutical composition | ELI LILLY AND COMPANY | 2004-02-03 | — | — | US | disclosed |
| CN-1396828-A | Pharmaceutical composition comprising Pemetrexed together with monothioglycerol L-cystein or thioglycolic acid | LILLY CO ELI (US) | 2003-02-12 | — | — | CN | disclosed |
| EP-1265612-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PEMETREXED TOGETHER WITH MONOTHIOGLYCEROL, L-CYSTEIN OR THIOGLYCOLIC ACID | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001056575-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PEMETREXED TOGETHER WITH MONOTHIOGLYCEROL L-CYSTEIN OR THIOGLYCOLIC ACID | ELI LILLY AND COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009199-A1 | PEMETREXED FORMULATIONS | MTHFD1, TYMP, DHFR | CA12 3869/4885CA1 4536/4885CA2 4307/4885 |
| US-20240009198-A1 | PEMETREXED FORMULATIONS | MTHFD1, TYMP, DHFR | CA12 3869/4885CA1 4536/4885CA2 4307/4885 |
| US-20160310495-A1 | PHARMACEUTICAL COMPOSITIONS OF PEMETREXED | TYMP, TYMS, HPRT1 | CA12 3578/4885CA1 4161/4885CA2 4034/4885 |
| US-20150111905-A1 | PHARMACEUTICAL COMPOSITIONS OF PEMETREXED | TYMP, TYMS, HPRT1 | CA12 3578/4885CA1 4161/4885CA2 4034/4885 |
| US-20230414623-A1 | PEMETREXED FORMULATIONS | MTHFD1, TYMP, DHFR | CA12 3869/4885CA1 4536/4885CA2 4307/4885 |
| US-20230390295-A1 | PEMETREXED FORMULATIONS | MTHFD1, TYMP, DHFR | CA12 3869/4885CA1 4536/4885CA2 4307/4885 |
| US-12115164-B2 | Pemetrexed formulations | MTHFD1, TYMP, DHFR | CA12 3869/4885CA1 4536/4885CA2 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.